PubMed
Oral intake of specific bioactive collagen peptides reduces skin wrinkles and improves dermal matrix synthesis
Proksch E, Schunck M, Zague V, et al. Skin Pharmacol Physiol. 2014
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 44% · Mixed 40% · Unfavorable overall 16%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 10–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 54% said they felt similar to their last entry, 36% more positive, and 14% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 34 days · Based on 268 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 49% · Mixed 36% · Unfavorable overall 15%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 1–2 mg · Most common: 0.6–1 mg
Reports span 0.2–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 29% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 514 repeat reporters
Published sources linked on the Collagen Peptides and Tirzepatide wiki pages.
PubMed
Proksch E, Schunck M, Zague V, et al. Skin Pharmacol Physiol. 2014
PubMed
García-Coronado JM, Martínez-Olvera L, Elizondo-Omaña RE, et al. Int Orthop. 2019
PubMed
Czajka A, Kania EM, Genovese L, et al. Nutrition research (New York, N.Y.). 2018
PubMed
Krečak I, Babić G, Skelin M. Acta dermatovenerologica Croatica : ADC. 2022
FDA Drug Label
Eli Lilly. FDA Drug Label. 2022
PubMed
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021
PubMed
Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024
FDA Drug Label
Eli Lilly. FDA Drug Label. 2023
PubMed
Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023
PubMed
Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025
PubMed
Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026
PubMed
Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024